Imunon Inc (IMNN) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: -$408.8K

AI summary pending

Imunon (IMNN) filed an 8-K on Aug. 11, 2026, to disclose that its Compensation Committee and Board approved stock-based pay programs for certain executives. CEO Stacy Lindborg can elect to receive up to 50% of base salary in common stock, Executive Chairman Michael Tardugno up to 100%, and Chief Medical Officer Douglas Faller up to 40%. On top of that, they get additional shares at varying rates depending on the pay date — for example, Lindborg's extra shares are 35% for shares issued on Aug. 14 and 17.5% for each pay date from Aug. 28 through Sept. 25, 2026. This is a routine executive-compensation disclosure, and the filing doesn't mention any operational changes, exact share counts, or financial results.

Imunon (IMNN), a biotech company, issued a press release on August 11, 2026, reporting its financial results for the quarter ended June 30, 2026. This 8-K simply attaches that press release and also notes that the company had announced on August 4 that it would hold a conference call on August 11 to discuss results and give a business update. The filing is a routine disclosure and doesn't include the actual revenue or profit figures in the text — those are in the press release and call.